Literature DB >> 16606869

Idiopathic macular telangiectasia.

Lawrence A Yannuzzi1, Anne M C Bardal, K Bailey Freund, Kuan-Jen Chen, Chiara M Eandi, Barbara Blodi.   

Abstract

OBJECTIVES: To review the frequency and nature of idiopathic macular telangiectasia and to classify the disorders based on new clinical and imaging observations.
METHODS: A combined retrospective and prospective analysis of newly diagnosed patients seen over a period of 3 years. Patients were identified based on the Gass-Blodi classification and were studied with biomicroscopy, fluorescein angiography, and optical coherence tomography.
RESULTS: Ten patients associated with aneurysmal telangiectasia (Gass-Blodi group 1) and 26 patients with perifoveal telangiectasia (Gass-Blodi group 2) were recruited. None with occlusive telangiectasia (Gass-Blodi group 3) were identified. New observations based on clinical, fluorescein angiographic, and optical coherence tomographic findings were made.
CONCLUSIONS: Our series was similar to that in the Gass-Blodi study in terms of frequency. New observations in groups 1 and 2 have expanded our knowledge of the clinical spectrum of these disorders. A simplified classification termed idiopathic macular telangiectasia with 2 distinct types (type I, or aneurysmal telangiectasia, and type II, or perifoveal telangiectasia) was proposed to produce a better understanding of the entities and to enhance teaching and research. The third type, occlusive telangiectasia, has been omitted from our classification based on its rarity and presence of capillary nonperfusion rather than macular telangiectasia as the primary abnormality.

Entities:  

Mesh:

Year:  2006        PMID: 16606869     DOI: 10.1001/archopht.124.4.450

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  118 in total

1.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  Retinal crystals in type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Irene Leung; Mina Chung; Ute E K Wolf-Schnurrbusch; Alfredo Dubra; David R Williams; Traci Clemons; Daniel Pauleikhoff; Alan C Bird; Tunde Peto
Journal:  Ophthalmology       Date:  2011-08-12       Impact factor: 12.079

3.  Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.

Authors:  Buğra Karasu; Betul Onal Gunay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-25       Impact factor: 3.117

4.  Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice.

Authors:  Jing Hua; Karen I Guerin; Jing Chen; Shaday Michán; Andreas Stahl; Nathan M Krah; Molly R Seaward; Roberta J Dennison; Aimee M Juan; Colman J Hatton; Przemyslaw Sapieha; David A Sinclair; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-25       Impact factor: 4.799

5.  Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density.

Authors:  Eric K Chin; Dae Yu Kim; Allan A Hunter; Suman Pilli; Machelle Wilson; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-02       Impact factor: 4.799

Review 6.  Resveratrol and the eye: activity and molecular mechanisms.

Authors:  Christina Bola; Hannah Bartlett; Frank Eperjesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-21       Impact factor: 3.117

7.  Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.

Authors:  Berna Dogan; Muhammet Kazim Erol; Melih Akidan; Elcin Suren; Yusuf Akar
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

8.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

9.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

10.  Prevalence and progression of pigment clumping associated with idiopathic macular telangiectasia type 2.

Authors:  Annal D Meleth; Brian C Toy; Divya Nigam; Elvira Agrón; Robert P Murphy; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2013-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.